Sustained API pricing pressure
API revenue declined 16% YoY due to pricing pressure from both domestic and import competition, which may persist.
AUROPHARMA / Q1-FY26 / risks
Keep the risk register visible.
Aurobindo Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
FTC approval delay for Lannett acquisition
The Lannett acquisition is subject to FTC approval, which could take 8-12 months or longer, delaying synergies.
Generic Revlimid revenue tailwind fading
Generic Revlimid sales have largely been exhausted, with minimal future contribution expected, impacting U.S. revenue.
U.S. tariff and domestic manufacturing push uncertainty
Potential U.S. tariffs and push for domestic manufacturing could increase costs and alter competitive dynamics.